%	O
%	O
TITLE	O

Contribution	O
of	O
human	O
papilloma	O
virus	O
to	O
the	O
incidence	B-Incidence_or_Prevalence
of	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
head	O
and	O
neck	O
in	O
a	O
European	B-Study_Location
population	O
with	O
high	O
smoking	O
prevalence	B-Incidence_or_Prevalence
.	O

%	O
%	O
ABSTRACT	O

Increases	O
in	O
incidence	B-Incidence_or_Prevalence
of	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
in	O
countries	O
with	O
falling	O
tobacco	O
use	O
have	O
been	O
attributed	O
to	O
a	O
growing	O
role	O
of	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
in	O
the	O
carcinogenesis	O
.	O

Trends	O
of	O
HPV	O
prevalence	B-Incidence_or_Prevalence
in	O
populations	O
with	O
persistently	O
high	O
portions	O
of	O
smokers	O
are	O
poorly	O
characterised	O
.	O
Registry	O
data	O
from	O
East	B-Study_Location
Germany	I-Study_Location
were	O
used	O
to	O
determine	O
incidence	B-Incidence_or_Prevalence
trends	O
between	O
1998	O
and	O
2011	O
.	O

Data	O
from	O
patients	B-Study_Cohort
treated	I-Study_Cohort
at	I-Study_Cohort
the	I-Study_Cohort
CharitÃ©	I-Study_Cohort
University	I-Study_Cohort
Medicine	I-Study_Cohort
Berlin	I-Study_Cohort
between	O
2004	B-Study_Time
and	I-Study_Time
2013	I-Study_Time
(	O
cohort	B-Study_Cohort
1	I-Study_Cohort
,	I-Study_Cohort
N=436	I-Study_Cohort
)	O
were	O
used	O
for	O
estimation	O
of	O
trends	O
in	O
HPV	O
prevalence	B-Incidence_or_Prevalence
,	O
smoking	O
and	O
survival	O
.	O

HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
prospectively	O
confirmed	O
in	O
cohort	B-Study_Cohort
2	I-Study_Cohort
(	I-Study_Cohort
N=213	I-Study_Cohort
)	I-Study_Cohort
comprising	O
all	O
primary	O
HNSCC	O
cases	O
at	O
the	O
CharitÃ©	O
in	O
2013	B-Study_Time
.	O
Between	O
1998	O
and	O
2011	O
incidence	B-Incidence_or_Prevalence
of	O
both	O
OPSCC	O
and	O
non	O
-	O
OPSCC	O
increased	O
.	O

An	O
increase	O
in	O
HPV	O
prevalence	B-Incidence_or_Prevalence
(	O
%	O
of	O
HPV	O
+	O
cases	O
in	O
2004	O
-	O
2006	O
versus	O
2012	O
-	O
2013	O
:	O
27	O
%	O
versus	O
59	O
%	O
,	O
P=0	O
.	O
0004	O
)	O
accompanied	O
by	O
a	O
moderate	O
decrease	O
in	O
the	O
portion	O
of	O
current	O
smokers	O
was	O
observed	O
in	O
OPSCC	O
but	O
not	O
in	O
non	O
-	O
OPSCC	O
.	O

The	O
change	O
in	O
disease	O
epidemiology	O
in	O
OPSCC	O
was	O
associated	O
with	O
significant	O
improvement	O
in	O
overall	O
survival	O
.	O

Increased	O
HPV	O
prevalence	B-Incidence_or_Prevalence
in	O
OPSCC	O
(	O
48	O
%	O
)	O
compared	O
to	O
non	O
-	O
OPSCC	O
(	O
11	O
%	O
)	O
was	O
confirmed	O
in	O
cohort	O
2	O
.	O
Despite	O
clear	O
differences	O
to	O
the	O
United	B-Study_Location
States	I-Study_Location
in	O
terms	O
of	O
tobacco	O
use	O
,	O
the	O
increase	O
in	O
OPSCC	O
incidence	O
in	O
a	O
European	B-Study_Location
population	O
was	O
also	O
mainly	O
attributed	O
to	O
HPV	O
,	O
and	O
the	O
HPV	O
status	O
significantly	O
affected	O
prognosis	O
.	O

For	O
clinical	O
trial	O
design	O
it	O
is	O
important	O
to	O
consider	O
the	O
large	O
group	O
of	O
smokers	O
within	O
HPV	O
-	O
induced	O
OPSCC	O
.	O

%	O
%	O
METHODS	O

Data	O
sources	O

We	O
used	O
data	O
from	O
the	O
Common	O
Tumor	O
Registry	O
of	O
the	O
federal	O
states	O
of	O
Berlin	O
,	O
Brandenburg	O
,	O
Mecklenburg	O
-	O
Western	O
Pomerania	O
,	O
Saxony	O
-	O
Anhalt	O
,	O
Saxony	O
and	O
Thurin	O
-	O
gia	O
(	O
1998–2011	O
)	O
.	O

Only	O
cases	O
with	O
squamous	O
cell	O
histology	O
were	O
included	O
.	O

Subsite	O
coding	O
was	O
according	O
to	O
the	O
ICD	O
-	O
O	O
-	O
3	O
classiﬁcation	O
,	O
and	O
subsite	O
grouping	O
was	O
done	O
in	O
accordance	O
with	O
Braakhuis	O
et	O
al	O
.	O
(	O
for	O
more	O
detail	O
see	O
available	O
online	O
)	O
.	O

Patient	O
characteristics	O

Two	B-Study_Cohort
patient	I-Study_Cohort
cohorts	I-Study_Cohort
were	O
included	O
for	O
assessment	O
of	O
HPV	O
prevalence	B-Incidence_or_Prevalence
trends	O
.	O

Cohort	B-Study_Cohort
1	I-Study_Cohort
consisted	I-Study_Cohort
of	I-Study_Cohort
patients	I-Study_Cohort
who	I-Study_Cohort
had	I-Study_Cohort
been	I-Study_Cohort
treated	I-Study_Cohort
at	I-Study_Cohort
the	I-Study_Cohort
Charite´	I-Study_Cohort
Radi	I-Study_Cohort
-	I-Study_Cohort
ooncology	I-Study_Cohort
and	I-Study_Cohort
Radiotherapy	I-Study_Cohort
department	I-Study_Cohort
within	O
the	O
last	O
10	O
years	O
,	O
consented	O
to	O
participate	O
in	O
studies	O
for	O
the	O
evaluation	O
of	O
prognostic	O
/	O
predictive	O
biomarkers	O
for	O
treatment	O
outcome	O
(	O
EA4	O
/	O
090	O
/	O
08	O
;	O
EA2	O
/	O
086	O
/	O
10	O
)	O
and	O
from	O
whom	O
the	O
HPV	O
status	O
of	O
the	O
primary	O
tumour	O
tissue	B-HPV_Sample_Type
had	O
been	O
determined	O
as	O
part	O
of	O
the	O
bio	O
-	O
marker	O
programme	O
.	O

Cohort	B-Study_Cohort
2	I-Study_Cohort
consisted	I-Study_Cohort
of	I-Study_Cohort
all	I-Study_Cohort
consec	I-Study_Cohort
-	I-Study_Cohort
utive	I-Study_Cohort
cases	I-Study_Cohort
who	I-Study_Cohort
presented	I-Study_Cohort
between	I-Study_Cohort
January	I-Study_Cohort
2013	I-Study_Cohort
and	I-Study_Cohort

516	I-Study_Cohort
I	I-Study_Cohort
.	I-Study_Cohort

Tinhofer	I-Study_Cohort
et	I-Study_Cohort
al	I-Study_Cohort
.	I-Study_Cohort
/	I-Study_Cohort
European	I-Study_Cohort
Journal	I-Study_Cohort
of	I-Study_Cohort
Cancer	I-Study_Cohort
51	I-Study_Cohort
(	I-Study_Cohort
2015	I-Study_Cohort
)	I-Study_Cohort
514–521	I-Study_Cohort

December	I-Study_Cohort
2013	I-Study_Cohort
at	I-Study_Cohort
the	I-Study_Cohort
Charite´	O
,	O
were	O
newly	O
diagnosed	O
for	O
HNSCC	O
and	O
had	O
been	O
discussed	O
at	O
the	O
interdisci	O
-	O
plinary	O
tumour	O
board	O
for	O
cancer	O
treatment	O
.	O

The	O
char	O
-	O
acteristics	O
of	O
the	O
two	B-Study_Cohort
patient	I-Study_Cohort
populations	I-Study_Cohort
from	I-Study_Cohort
cohorts	I-Study_Cohort

1	I-Study_Cohort
(	I-Study_Cohort
N	I-Study_Cohort
=	I-Study_Cohort
436	I-Study_Cohort
)	I-Study_Cohort
and	I-Study_Cohort
2	I-Study_Cohort
(	I-Study_Cohort
N	I-Study_Cohort
=	I-Study_Cohort
213	I-Study_Cohort
)	I-Study_Cohort
are	O
detailed	O
in	O

available	O
online	O
.	O

Assessment	O
of	O
HPV	O
status	O

HPV	O
status	O
was	O
determined	O
using	O
a	O
two	O
-	O
step	O
algo	O
-	O
rithm	O
:	O
ﬁrst	O
,	O
p16Ink4	B-HPV_Lab_Technique
protein	I-HPV_Lab_Technique
expression	I-HPV_Lab_Technique
as	I-HPV_Lab_Technique
surrogate	I-HPV_Lab_Technique
marker	I-HPV_Lab_Technique
for	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
was	I-HPV_Lab_Technique
assessed	I-HPV_Lab_Technique
by	I-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
in	O
all	O
cases	O
.	O

Tumour	O
samples	B-HPV_Sample_Type
showing	O
strong	O
,	O
diﬀuse	O
cytoplasmic	O
and	O
nuclear	O
staining	O
of	O
p16	O
in	O
>	O
10	O
%	O
of	O
car	O
-	O

cinoma	O
cells	O
were	O
subjected	O
to	O
Luminex®	O
-	O
based	O
mul	O
-	O

tiplexed	O
genotyping	O
for	O
detection	O
of	O
HPV	O
-	O
speciﬁc	O
DNA	O
.	O

Only	O
cases	O
positive	O
for	O
both	O
p16	O
(	O
deﬁned	O
by	O
strong	O
nuclear	O
staining	O
in	O
>	O
70	O
%	O
cells	O
)	O
and	O
HPV	O
DNA	O
were	O
considered	O
to	O
be	O
‘true	O
HPV	O
-	O
positive’	O
.	O

Details	O
on	O
p16	B-HPV_Lab_Technique
immunohistochemistry	I-HPV_Lab_Technique
and	O
HPV	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
genotyping	I-HPV_Lab_Technique
are	O
provided	O
as	O
online	O
.	O

Statistical	O
analysis	O

Average	O
annual	O
percent	O
changes	O
in	O
European	O
age	O
-	O
standardised	O
rates	O
per	O
100	O
,	O
000	O
inhabitants	O
(	O
ESR	O
)	O
were	O
calculated	O
and	O
signiﬁcant	O
changes	O
in	O
trends	O
were	O
determined	O
using	O
the	O
jointpoint	O
regression	O
programme	O
(	O
version	O
4	O
.	O
1	O
.	O

1	O
)	O
provided	O
as	O
free	O
download	O
at	O
the	O
home	O
-	O
page	O
of	O
the	O
Surveillance	O
,	O
Epidemiology	O
and	O
End	O
Results	O
Program	O
.	O

Overall	O
and	O
progression	O
-	O
free	O
survival	O
was	O
compared	O
by	O
using	O
Kaplan–Meier	O
analysis	O
and	O
the	O
log	O
-	O
rank	O
test	O
.	O

Interactions	O
between	O
time	O
of	O
ﬁrst	O
diagno	O
-	O
sis	O
,	O
clinical	O
parameters	O
and	O
overall	O
survival	O
were	O
evaluated	O
using	O
the	O
Cox	O
regression	O
model	O
.	O

Statistical	O
analyses	O
were	O
carried	O
out	O
using	O
the	O
SPSS	O
Statistics	O
software	O
(	O
version	O
22	O
.	O
0	O
.	O

0	O
,	O
IBM	O
,	O
Armonk	O
,	O
NY	O
,	O
USA	O
)	O
.	O

The	O
level	O
of	O
signiﬁcance	O
was	O
set	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

Results	O

Incidence	B-Incidence_or_Prevalence
trends	O
for	O
HNSCC	O
between	O
1998	O
and	O
2011	O

During	O
the	O
observation	O
period	O
of	O
14	O
years	O
increasing	O
trends	O
in	O
the	O
incidence	B-Incidence_or_Prevalence
were	O
observed	O
for	O
both	O
genders	O
in	O
all	O
main	O
HNSCC	O
sites	O
(	O
)	O
.	O

The	O
increase	O
in	O
incidence	B-Incidence_or_Prevalence
was	O
more	O
pronounced	O
for	O
carcinomas	O
of	O
the	O
oral	O
cavity	O
and	O
oropharynx	O
compared	O
to	O
the	O
two	O
other	O
subsites	O
.	O

Interestingly	O
,	O
an	O
apparent	O
change	O
in	O
carcinoma	O
rates	O
of	O
the	O
oral	O
cavity	O
and	O
the	O
oropharynx	O
was	O
recorded	O
exclusively	O
for	O
males	O
:	O
While	O
incidences	B-Incidence_or_Prevalence
were	O
increasing	O
in	O
the	O
period	O
of	O
1998–2007	O
,	O
a	O
plateau	O
phase	O
was	O
reached	O
with	O
no	O
signiﬁcant	O
changes	O
thereafter	O
(	O
)	O
.	O

Prevalence	B-Incidence_or_Prevalence
trends	O
of	O
HPV	O
-	O
associated	O
HNSCC	O
:	O
a	O
retrospective	B-Study_Type
cohort	I-Study_Type
analysis	I-Study_Type

In	O
total	O
,	O
118	O
of	O
436	O
carcinomas	O
(	O
27	O
%	O
)	O
in	O
cohort	O
1	O
were	O
HPV	O
-	O
positive	O
.	O

As	O
expected	O
,	O
HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
signiﬁcantly	O
higher	O
in	O
OPSCC	O
compared	O
to	O
non	O
-	O
OPSCC	O
(	O
%	O
HPV	O
+	O
cases	O
:	O
OPSCC	O
,	O
40	O
%	O
;	O
non	O
-	O
OPSCC	O
:	O
13	O
%	O
;	O

P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Overall	O
,	O
286	O
of	O
436	O
patients	O
(	O
66	O
%	O
)	O
were	O
cur	O
-	O

rent	O
smokers	O
.	O

HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
higher	O
in	O
the	O
group	O
of	O
never	O
/	O
ex	O
-	O
smokers	O
compared	O
to	O
current	O
smokers	O
(	O
%	O
HPV	O
+	O
cases	O
:	O
never	O
/	O
ex	O
-	O
smokers	O
,	O
37	O
%	O
;	O
current	O
smokers	O
:	O
22	O
%	O
;	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

No	O
diﬀerence	O
in	O
the	O
age	O
at	O
ﬁrst	O
diagno	O
-	O
sis	O
was	O
observed	O
between	O
HPV	O
+	O
and	O
HPV	O
cases	O
(	O
mean	O
years	O
±	O
standard	O
deviation	O
:	O
HPV	O
cases	O
,	O
58	O
±	O
9	O
;	O
HPV	O
+	O
cases	O
:	O
60	O
±	O
9	O
;	O
P	O
=	O
0	O
.	O
21	O
)	O
.	O

For	O
time	O
trend	O
analysis	O
patients	O
were	O
stratiﬁed	O
into	O

four	O
calendar	O
period	O
groups	O
using	O
the	O
time	O
of	O
ﬁrst	O
diagnosis	O
as	O
stratiﬁcation	O
parameter	O
.	O

HPV	O
prevalence	B-Incidence_or_Prevalence
signiﬁcantly	O
increased	O
across	O
calendar	O
periods	O
in	O
OPS	O
-	O
CC	O
(	O
A	O
)	O
.	O

Interestingly	O
,	O
the	O
increase	O
in	O
the	O
relative	O
number	O
of	O
HPV	O
+	O
cases	O
among	O
OPSCC	O
did	O
not	O
start	O
before	O
2010	O
but	O
HPV	O
prevalence	B-Incidence_or_Prevalence
nonetheless	O
increased	O

Fig	O
.	O

1	O
.	O

Incidence	B-Incidence_or_Prevalence
trends	O
for	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
by	O
anatomical	O
site	O
and	O
gender	O
in	O
East	B-Study_Location
Germany	I-Study_Location
.	O

Incidence	B-Incidence_or_Prevalence
is	O
expressed	O
as	O
ESR	O
,	O
the	O
European	B-Study_Location
age	O
-	O
standardised	O
rate	O
per	O
100	O
,	O
000	O
inhabitants	O
.	O

Tinhofer	O
et	O
al	O
.	O
/	O
European	B-Study_Location
Journal	O
of	O
Cancer	O
51	O
(	O
2015	O
)	O
514–521	O
517	O

Table	O
1	O

Estimated	O
annual	O
percentage	O
changes	O
in	O
European	B-Study_Location
age	O
-	O
standardised	O
rates	O
(	O
EASR	O
)	O
.	O

(	O
-	O
8	O
.	O
7	O
;	O
+	O
3	O
.	O
8	O
)	O

(	O
+	O
0	O
.	O
5	O
;	O
+	O
4	O
.	O
8	O
)	O

*	O
European	B-Study_Location
age	O
-	O
standardised	O
rates	O
per	O
100	O
,	O
000	O
inhabitants	O
(	O
ESR	O
)	O
.	O

#	O
Average	O
annual	O
percentage	O
changes	O
.	O

Fig	O
.	O

2	O
.	O

Prevalence	B-Incidence_or_Prevalence
of	O
human	O
papilloma	O
virus	O
(	O
HPV	O
)	O
and	O
current	O
smokers	O
in	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
and	O
non	O
-	O
OPSCC	O
.	O

The	O
results	O
from	O
time	O
-	O
dependent	O
analysis	O
of	O
HPV	O
prevalence	B-Incidence_or_Prevalence
and	O
smoking	O
status	O
in	O
cohort	O
1	O
are	O
shown	O
for	O
OPSCC	O
(	O
A	O
)	O
and	O
non	O
-	O
OPSCC	O
(	O
B	O
)	O
.	O

The	O
relative	O
portions	O
of	O
HPV	O
+	O
cases	O
and	O
current	O
smokers	O
in	O
cohort	O
2	O
(	O
C	O
)	O
are	O
presented	O
.	O

more	O
than	O
twofold	O
between	O
2004–2006	O
(	O
28	O
%	O
)	O
and	O
2012–2013	O
(	O
59	O
%	O
)	O
.	O

Although	O
the	O
increase	O
in	O
HPV	O
prev	B-Incidence_or_Prevalence
-	I-Incidence_or_Prevalence
alence	I-Incidence_or_Prevalence
was	O
paralleled	O
by	O
a	O
decrease	O
in	O
the	O
portion	O
of	O
current	O
smokers	O
among	O
OPSCC	O
patients	O
the	O
change	O
in	O
the	O
smoking	O
habits	O
was	O
less	O
pronounced	O
,	O
with	O
a	O
reduction	O
of	O
only	O
22	O
%	O
during	O
the	O
same	O
period	O
of	O
time	O
.	O

In	O
non	O
-	O
OPSCC	O
,	O
no	O
signiﬁcant	O
change	O
in	O
HPV	O
prevalence	B-Incidence_or_Prevalence
was	O
observed	O
and	O
the	O
portion	O
of	O
current	O
smokers	O
even	O
increased	O
per	O
trend	O
over	O
time	O
in	O
this	O
group	O
of	O
patients	O
(	O
B	O
)	O
.	O

Prevalence	B-Incidence_or_Prevalence
trends	O
of	O
HPV	O
-	O
associated	O
HNSCC	O
:	O
a	O
prospective	B-Study_Type
survey	I-Study_Type
analysis	I-Study_Type

Since	O
cohort	O
1	O
represented	O
a	O
collection	O
of	O
patients	O
participating	O
in	O
biomarker	O
studies	O
a	O
selection	O
bias	O
with	O
impact	O
on	O
HPV	O
prevalence	B-Incidence_or_Prevalence
trends	O
cannot	O
be	O
excluded	O
.	O

In	O
order	O
to	O
conﬁrm	O
the	O
results	O
on	O
current	O
HPV	O
prevalence	B-Incidence_or_Prevalence
we	O
prospectively	O
assessed	O
the	O
HPV	O
sta	O
-	O
tus	O
in	O
cohort	O
2	O
representing	O
all	O
primary	O
HNSCC	O
cases	O
who	O
presented	O
within	O
1	O
year	O
(	O
January	O
2013–December	O

518	O
I	O
.	O

Tinhofer	O
et	O
al	O
.	O
/	O
European	O
Journal	O
of	O
Cancer	O
51	O
(	O
2015	O
)	O
514–521	O

Fig	O
.	O

3	O
.	O

Trends	O
in	O
overall	O
and	O
progression	O
-	O
free	O
survival	O
in	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
(	O
left	O
)	O
and	O
non	O
-	O
OPSCC	O
(	O
right	O
)	O
.	O

Table	O
2	O

Hazard	O
ratios	O
for	O
OS	O
in	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
,	O
according	O
to	O
patient	O
group	O
.	O

Fig	O
.	O

4	O
.	O

Trends	O
in	O
smoking	O
habits	O
in	O
HPV	O
+	O
OPSCC	O
(	O
A	O
)	O
and	O
its	O
interference	O
with	O
overall	O
survival	O
(	O
B	O
)	O
.	O

2013	O
)	O
for	O
diagnosis	O
and	O
treatment	O
at	O
the	O
Charite´	O
.	O

We	O
observed	O
a	O
prevalence	B-Incidence_or_Prevalence
of	O
48	O
%	O
of	O
HPV	O
+	O
cases	O
in	O
OPSCC	O
and	O
their	O
speciﬁc	O
enrichment	O
in	O
OPSCC	O
compared	O
to	O
non	O
-	O
OPSCC	O
(	O
11	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Again	O
,	O
increased	O
preva	B-Incidence_or_Prevalence
-	I-Incidence_or_Prevalence
lence	I-Incidence_or_Prevalence
of	O
HPV	O
was	O
observed	O
despite	O
a	O
persistently	O
high	O
por	O
-	O
tion	O
of	O
current	O
smokers	O
in	O
the	O
group	O
of	O
OPSCC	O
(	O
C	O
)	O
.	O

Patient	O
outcome	O
is	O
aﬀected	O
by	O
the	O
epidemiologic	O
shift	O
in	O
OPSCC	O
but	O
not	O
non	O
-	O
OPSCC	O

Several	O
studies	O
have	O
previously	O
demonstrated	O
supe	O
-	O
rior	O
outcome	O
of	O
HPV	O
+	O
compared	O
to	O
HPV	O
-	O
OPSCC	O

patients	O
.	O

This	O
was	O
irrespective	O
of	O
the	O
type	O
of	O
treatment	O
tested	O
in	O
these	O
studies	O
,	O
being	O
either	O
radiation	O
,	O
chemo	O
-	O
radiation	O
,	O
cetuximab	O
-	O
based	O
bioradiation	O
or	O
che	O
-	O
motherapy	O
in	O
the	O
neoadjuvant	O
or	O
palliative	O
setting	O
.	O

We	O
tested	O
whether	O
the	O
increasing	O
trends	O
in	O
HPV	O
prevalence	B-Incidence_or_Prevalence
observed	O
in	O
cohort	O
1	O
were	O
also	O
associated	O
with	O
improved	O
outcome	O
.	O

As	O
shown	O
in	O
,	O
we	O
observed	O
signiﬁcantly	O
improved	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
a	O
trend	O
towards	O
better	O
PFS	O
in	O
OPSCC	O
patients	O
with	O
diagnosis	O
and	O
treatment	O
between	O
2010	O
and	O
2013	O
compared	O
to	O
patients	O
diagnosed	O
before	O
2010	O
.	O

The	O
2	O
-	O
year	O
OS	O
rates	O
±95	O
%	O
conﬁdence	O
intervals	O
were	O
71	O
%	O

Tinhofer	O
et	O
al	O
.	O
/	O
European	O
Journal	O
of	O
Cancer	O
51	O
(	O
2015	O
)	O
514–521	O
519	O

(	O
61–80	O
%	O
)	O
and	O
50	O
%	O
(	O
40–59	O
%	O
)	O
,	O
respectively	O
.	O

This	O
signiﬁ	O
-	O
cant	O
diﬀerence	O
in	O
OS	O
between	O
the	O
two	O
OPSCC	O
groups	O
was	O
still	O
observed	O
after	O
correction	O
for	O
Union	O
for	O
Interna	O
-	O
tional	O
Cancer	O
Control	O
(	O
UICC	O
)	O
stage	O
and	O
type	O
of	O
treat	O
-	O
ment	O
(	O
radiation	O
versus	O
chemoradiation	O
)	O
in	O
multivariate	O
analysis	O
(	O
)	O
.	O

No	O
improvement	O
of	O
OS	O
or	O
PFS	O
was	O
observed	O
for	O
the	O
group	O
of	O
non	O
-	O
OPSCC	O
patients	O
(	O
,	O
right	O
panel	O
)	O
.	O

Smoking	O
habits	O
remain	O
an	O
independent	O
risk	O
of	O
death	O
in	O
HPV	O
+	O
OPSCC	O

Smoking	O
has	O
previously	O
been	O
identiﬁed	O
as	O
indepen	O
-	O
dent	O
risk	O
factor	O
for	O
tumour	O
recurrence	O
and	O
death	O
also	O
in	O
patients	O
with	O
HPV	O
-	O
driven	O
carcinomas	O
.	O

Since	O
we	O
observed	O
a	O
persistently	O
high	O
prevalence	B-Incidence_or_Prevalence
of	O
current	O
smokers	O
in	O
OPSCC	O
even	O
in	O
patients	O
with	O
an	O
HPV	O
+	O
car	O
-	O
cinoma	O
(	O
)	O
,	O
we	O
evaluated	O
whether	O
outcome	O
is	O
com	O
-	O
promised	O
by	O
smoking	O
habits	O
in	O
patients	O
with	O
HPV	O
+	O
tumours	O
.	O

While	O
only	O
one	O
death	O
was	O
observed	O
in	O
the	O
group	O
of	O
patients	O
who	O
never	O
smoked	O
or	O
quit	O
smoking	O
at	O
least	O
one	O
year	O
before	O
ﬁrst	O
diagnosis	O
(	O
N	O
=	O
50	O
)	O
,	O
10	O

patients	O
from	O
the	O
group	O
of	O
current	O
smokers	O
(	O
N	O
=	O
41	O
)	O

died	O
from	O
their	O
disease	O
(	O
)	O
.	O

